| Currently, rotavirus vaccination is not recommended in France due to safety concerns over intussusception caused by vaccination. |
| We performed a benefit–risk analysis in France to compare estimated vaccine benefits (prevented gastroenteritis) with potential vaccine-related risks (excess intussusception). |
| Our benefit–risk analysis predicts that the number of prevented rotavirus gastroenteritis hospitalizations and deaths would be 1624 [95% credible interval (CI) 240–5243] and 743 (95% CI 93–3723) times higher, respectively, than the excess intussusception hospitalizations or deaths potentially caused by vaccination. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.